1. Introduction

Capital gains in biotechnology exits refers to the profit earned when founders, investors, employees, or other shareholders dispose of their ownership interests in a biotechnology business. An exit may occur through an acquisition, a sale of shares, a merger, an initial public offering (IPO), a buyback, or the sale of intellectual property and other business assets.

Biotech exits raise distinctive tax and legal issues because biotechnology companies frequently hold valuable assets that are difficult to value independently, including patents, gene-sequencing technologies, drug candidates, clinical-trial data, biological materials, software, and regulatory approvals.

The central legal questions are:

When does a taxable capital gain arise?

Is the transaction a share sale, an asset sale, or a reorganisation?

How should patents, research rights, and contingent acquisition payments be valued?

Does the seller qualify for long-term capital gains treatment?

Can a tax authority challenge the transaction's structure or valuation?

How do cross-border rules, employee equity, and investor agreements affect the exit?

The answer depends on the applicable jurisdiction, the seller's tax status, the nature of the asset, and the structure of the transaction. The following discussion focuses primarily on Indian law, with comparative principles from United States and United Kingdom case law where relevant.

This is a general legal analysis, not transaction-specific tax advice.

2. Common biotech exit structures

Novartis Drops $12B on Avidity as Pharma M&A Heats Up | The Tech Buzz

A. Sale of shares

Founders, venture-capital funds, or other shareholders sell shares to a pharmaceutical company or another investor. The seller's gain is generally measured by the consideration received less the applicable tax cost and allowable expenses.

Transforming Drug Discovery Through Chemical Biology

B. Sale of business assets or intellectual property

The company sells patents, licensing rights, a drug-development platform, or an entire business undertaking. The tax treatment may differ for each asset, and a sale of an undertaking as a going concern may be subject to special rules.

A Sanofi vai adquirir a Dynavax por US$ 2,2 bilhões, fazendo com que as ações subam 37% — TradingView News

C. Merger or tax-deferred reorganisation

Shares or assets are transferred as part of a qualifying amalgamation, demerger, or corporate restructuring. Tax neutrality is not automatic: statutory conditions and the identity of the transferor and transferee matter.

Biotech SOTP Valuation | Wall Street Prep

D. IPO, buyback, or contingent exit

An IPO may permit shareholders to sell listed shares; a buyback has its own tax rules; and an acquisition may include deferred consideration, escrow, milestone payments, or royalties tied to regulatory approval or commercial success.

3. How capital gains are calculated

The basic calculation is:

\[ \text{Capital Gain} = \text{Full Value of Consideration} -\text{Transfer Expenses} -\text{Cost of Acquisition} -\text{Allowable Improvement Costs} \]

The actual statutory calculation can differ by jurisdiction and asset class. In India, the Income-tax Act, 1961 has historically governed these calculations, while the Income-tax Act, 2025 is scheduled to apply from 1 April 2026. For a transaction occurring now, the relevant provisions and transition rules must be checked under the new Act.

Example: Founder sells biotech shares

Assume a founder sells shares in an Indian biotech company for ₹5 crore, with an acquisition cost of ₹50 lakh and eligible transfer expenses of ₹10 lakh.

This ₹4.4 crore is the illustrative gain before applying any relevant exemptions, loss adjustments, special valuation provisions, or other statutory adjustments. It is not the amount of tax payable.

The applicable rate depends on factors such as whether the shares are listed or unlisted, the holding period, the seller's residency, the acquisition date, and the law in force on the transfer date.

4. Applicable Indian legal framework

For transfers taking place in the current tax regime, the principal starting point is the Income-tax Act, 2025, effective from 1 April 2026. The corresponding provisions of the former 1961 Act remain relevant to earlier transactions and to the extent that transitional rules preserve their application. The government has described the new Act as a restructuring and simplification of the direct-tax framework.

Etds+1

The official text of sections 67, 72 and 197 is available through the Income Tax Department and IndiaCode.

IndiaCode+2

Important distinction: the section 197 rate is not automatically the rate for every biotech exit. Listed equity, unlisted shares, foreign investments, depreciable assets and other transaction types may be subject to different provisions.

5. Short-term versus long-term capital gains

The holding period can materially affect the seller's tax burden. The applicable threshold depends on the type of capital asset and the rules governing the relevant transfer.

For qualifying listed equity transactions under the previous Act's special provisions, the rate changes introduced from 23 July 2024 included a 20% rate for specified short-term gains and a 12.5% rate for specified long-term gains, subject to statutory conditions and thresholds. The corresponding rules and cross-references under the current Act must be checked before calculating tax.

Etds+1

A founder should not assume that all shares held for a particular number of months qualify for the same tax treatment as listed shares. The listing status, acquisition date, transfer date, and applicable provisions all matter.

6. Sale of shares versus sale of assets

One of the most important decisions in a biotech acquisition is whether the buyer purchases the shares of the company or purchases the underlying business assets.

Share sale

The existing company generally continues to own its patents, licences, contracts and research assets.

The seller is typically the shareholder.

The gain is calculated on the shares sold, subject to the applicable cost-basis and tax rules.

The buyer may inherit commercial, regulatory, contractual and historical tax risks through the acquired company.

Asset sale

The company itself sells the patents, research platform, equipment or business undertaking.

The company may recognise taxable gains on the assets transferred.

A subsequent distribution of the sale proceeds to shareholders may trigger additional tax consequences, depending on how the distribution is structured.

The tax treatment of a lump-sum going-concern sale may differ from the treatment of separately transferred assets.

Why the distinction matters

Suppose a pharmaceutical company offers ₹100 crore for a biotech startup.

In a share acquisition, shareholders receive the sale proceeds and their capital gains are generally computed on their shares.

In an asset acquisition, the biotech company receives the proceeds and must determine the tax treatment of each transferred asset or the undertaking as a whole.

In a qualifying tax-neutral reorganisation, the transaction may receive statutory relief if all applicable conditions are met.

The commercial purchase price alone does not determine the tax result. The legal ownership of each asset, the seller's identity, the form of consideration and the statutory conditions must be examined.

7. Valuation of patents, clinical data and drug-development rights

Biotechnology acquisitions often involve assets whose value depends on future scientific and commercial success. A patent may have limited value before clinical validation but become extremely valuable after successful trials or regulatory approval.

Common valuation methods include:

Discounted cash flow: estimates future cash flows from the product or technology and discounts them for time and risk.

Comparable transactions: uses prices paid for similar patents, licensing rights or biotechnology businesses.

Relief-from-royalty: estimates the value of owning intellectual property by reference to royalties that would otherwise have been payable.

Probability-adjusted pipeline valuation: estimates the potential value of drug candidates while accounting for clinical failure, regulatory delays and commercial uncertainty.

These methods are relevant to negotiating a defensible transaction value. They do not automatically establish the tax cost of an asset or settle the statutory meaning of sale consideration.

Special issue: self-developed intellectual property

A biotech company may have spent ₹40 crore on research, clinical trials, personnel and laboratory work, yet those expenditures do not necessarily become the tax cost of a patent or other asset for capital-gains purposes.

The analysis must distinguish between:

Research expenditure deducted as a business expense.

Expenditure capitalised into an asset.

Patent rights acquired from another party.

Internally generated intellectual property for which the applicable law may prescribe a special or deemed cost.

The transfer of an entire business undertaking rather than an isolated patent.

Practical consequence: a seller should reconcile the transaction valuation with the company's tax records, intellectual-property ownership documents, capitalisation policies and research-expense treatment. A commercial valuation of ₹50 crore does not mean the seller has a tax cost of ₹50 crore.

8. Important case laws governing biotech exits

There is no single Indian Supreme Court judgment establishing a special capital-gains regime for biotechnology exits. The following decisions provide important general principles that can apply to biotech acquisitions, particularly those involving intangible assets, cross-border share transfers and valuation disputes.

1. CIT v. B.C. Srinivasa Setty

Supreme Court of India · (1981) 128 ITR 294 (SC)

Legal principle: Capital-gains charging and computation provisions must be read together.

The Court considered whether transferring self-generated goodwill could attract capital-gains tax when its acquisition cost could not be determined under the then-applicable computation rules. It held that the charging provision could not operate where the statutory computation mechanism could not be applied.

Application to biotechnology: A startup may generate valuable know-how, research capability, reputation and technology internally. The judgment provides a historical analytical principle for examining the tax cost of self-generated intangible assets. However, it does not create a blanket exemption for modern intellectual property: later statutory amendments prescribe costs for specified assets, and the current law must be examined asset by asset.

NearLaw+1

2. CIT v. D.P. Sandu Bros. Chembur (P) Ltd.

Supreme Court of India · (2005) 273 ITR 1 (SC)

Legal principle: The statutory computation rules determine whether a receipt can be charged under the capital-gains head.

The dispute concerned consideration received for surrendering tenancy rights. The Court examined the relationship between the charging and computation provisions and the treatment of the asset under the law then in force.

Application to biotechnology: When a seller receives payment for surrendering a licence, research right or contractual entitlement, the legal character of that right and the applicable computation provisions must be identified. A payment described as an “exit fee” is not automatically a capital gain; it could have a different tax character depending on the transaction.

Indian Kanoon+1

3. Vodafone International Holdings B.V. v. Union of India

Supreme Court of India · (2012) 6 SCC 613

Legal principle: The legal form and substance of an offshore share transaction matter when determining Indian tax jurisdiction.

The case concerned Vodafone's acquisition of shares in a foreign company holding an indirect interest in an Indian telecommunications business. The Supreme Court ruled in Vodafone's favour under the law as it stood at the time.

Parliament subsequently enacted provisions dealing with indirect transfers of Indian assets. Accordingly, the judgment must not be read as establishing that all offshore acquisitions involving Indian businesses are tax-free.

Application to biotechnology: If a foreign pharmaceutical group acquires a holding company that indirectly owns an Indian biotech subsidiary, the analysis should cover indirect-transfer provisions, the location and value of underlying Indian assets, treaty entitlement and any applicable reporting or withholding obligations.

VoxJuris+1

9. Additional judicial principles

Other cases can help frame disputes arising in biotech exits.

These cases concern general tax principles rather than biotechnology-specific exit transactions. Their relevance depends on the precise statutory issue in dispute.

10. Earn-outs, milestone payments and contingent consideration

Biotech acquisitions often involve payments tied to clinical-trial success, regulatory approval or commercial sales.

For example, a buyer might offer:

₹20 crore at closing;

₹15 crore if a drug candidate obtains regulatory approval; and

royalties if annual product sales exceed an agreed threshold.

The tax questions include when the contingent amount is regarded as received or accruing, whether it forms part of the consideration for the original transfer, how it should be valued and whether any later payment has a different legal character.

Illustrative example: A founder sells shares for ₹20 crore at closing and may receive another ₹15 crore after regulatory approval. The initial amount and the contingent payment should be analysed under the applicable rules governing the transaction and the contractual rights created. It would be unsafe to assume that all tax is necessarily payable only when the final milestone cash is received.

The sale agreement should expressly address:

Whether milestone payments are contingent consideration for shares, assets or services.

Whether the seller must continue working for the buyer to qualify for payment.

How the payment is calculated and verified.

Whether amounts are held in escrow or subject to indemnity claims.

Which party bears any withholding-tax obligations.

How subsequent adjustments will be documented in tax filings.

Payments linked to continued employment or post-acquisition services may require a separate income-characterisation analysis rather than automatically being treated as capital gains.

11. Employee stock options and founder equity

Biotech employees and founders may receive stock options, restricted shares or other equity-linked compensation.

The tax analysis commonly involves two separate events:

At exercise or allotment: a taxable employment benefit may arise under the applicable rules.

At subsequent sale: the difference between the relevant tax cost and the sale consideration may give rise to capital gains.

The precise timing, valuation, cost basis and applicable relief depend on the equity instrument and the seller's circumstances.

For a startup, maintaining accurate records of option grants, vesting, exercise prices, allotments and share transfers is essential. Poor documentation can create disputes about both the amount of the taxable employment benefit and the subsequent capital gain.

12. Cross-border biotech exits and treaty considerations

A biotech company may have an Indian operating subsidiary, a foreign holding company, offshore venture-capital investors and intellectual-property rights registered in multiple countries.

Cross-border exits may therefore involve:

Indian domestic tax rules on direct or indirect transfers;

double-taxation agreements and their eligibility requirements;

beneficial ownership and anti-abuse provisions;

withholding tax and remittance documentation;

transfer pricing where related parties are involved;

foreign-exchange and corporate-law compliance; and

the possible taxation of gains in more than one jurisdiction.

A treaty should not be assumed to eliminate Indian tax simply because the seller is incorporated or resident overseas. Treaty eligibility, domestic charging provisions, applicable amendments and the actual transaction structure must all be considered.

13. Tax-neutral reorganisations and business transfers

Some reorganisations can qualify for tax-neutral treatment when the relevant statutory conditions are satisfied. This may be relevant where a pharmaceutical buyer acquires a biotech undertaking through a merger, demerger or another qualifying restructuring.

However, the transaction documents should distinguish a qualifying statutory reorganisation from an ordinary taxable sale.

The analysis should address:

the identity of the transferor and transferee;

the legal form of consideration;

continuity of ownership or business where required;

whether the relevant assets qualify under the statutory provisions;

the treatment of accumulated losses and depreciation; and

compliance with the applicable corporate and tax procedures.

A transaction labelled a “merger” or “reorganisation” does not automatically qualify for tax neutrality.

14. Common litigation risks in biotech exits

Valuation disputes

The tax authority may question the consideration or valuation methodology, particularly where a transaction involves related parties, unusual pricing or contingent intellectual-property rights.

Incorrect classification

A payment for shares, a patent licence, consultancy services or a research milestone may have different tax consequences even if the acquisition agreement groups them together.

Cross-border exposure

Indirect transfers, treaty eligibility and withholding obligations can create substantial liabilities if the parties rely on an incomplete jurisdictional analysis.

Insufficient records

Missing acquisition documents, incomplete intellectual-property ownership records and inconsistent research-expense treatment can undermine the claimed tax cost.

15. Practical checklist before closing a biotech exit

A founder, investor or company considering an exit should ordinarily review the following matters with qualified tax and transaction advisers.

Exit due-diligence checklist

0 of 8

Confirm whether the transaction is a share sale, asset sale, business transfer or qualifying reorganisation.

Identify the seller, tax residence and beneficial ownership of each relevant asset or shareholding.

Verify acquisition dates, holding periods, costs and allowable transfer expenses.

Prepare defensible valuations for patents, research rights, drug candidates and contingent consideration.

Review employee equity, vesting conditions, earn-outs, escrow and indemnity arrangements.

Analyse applicable domestic tax, treaty provisions, withholding and indirect-transfer exposure.

Check the current statutory provisions and any transitional rules governing the transaction date.

Retain executed agreements, valuation reports, share registers, patent records and supporting tax documentation.

Copy checklist

16. Conclusion

Capital gains in biotech exits are governed by the interaction of tax law, intellectual-property ownership, valuation, corporate structuring and the contractual terms of the exit.

The most important lessons are:

Structure matters: selling shares is legally and fiscally different from selling patents or an entire business.

Valuation and tax cost are different concepts: a patent's commercial value does not automatically establish its deductible tax cost.

Contingent consideration needs careful drafting: milestones and earn-outs can create timing and classification disputes.

Cross-border exits require jurisdiction-specific analysis: treaty benefits and offshore holding structures do not automatically eliminate Indian tax.

Case law must be applied with current legislation: earlier Supreme Court judgments remain important, but statutory amendments and the Income-tax Act, 2025 must be taken into account for current transactions.

For a real exit, the decisive questions are the precise asset being transferred, the seller's tax residence, the acquisition and sale dates, the form of consideration, and whether any specific exemption or reorganisation provision applies.